Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial

BACKGROUND: In MONARCH 2, abemaciclib plus fulvestrant significantly improved median progression-free survival (PFS, 16.4 vs 9.3 months, hazard ratio [HR] 0.553) and overall survival (OS, 46.7 vs 37.3 months; HR 0.757) compared with placebo plus fulvestrant in hormone receptor-positive (HR-positive)...

Descripción completa

Detalles Bibliográficos
Autores principales: Neven, Patrick, Rugo, Hope S., Tolaney, Sara M., Iwata, Hiroji, Toi, Masakazu, Goetz, Matthew P., Kaufman, Peter A., Lu, Yi, Haddad, Nadine, Hurt, Karla C., Sledge, George W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381581/
https://www.ncbi.nlm.nih.gov/pubmed/34425869
http://dx.doi.org/10.1186/s13058-021-01463-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381581/
https://www.ncbi.nlm.nih.gov/pubmed/34425869
http://dx.doi.org/10.1186/s13058-021-01463-2

Ejemplares similares